Business Context and Reporting Period
This Form 6-K filing is submitted by pSivida Limited, a foreign issuer, for the month of April 2006. The report was signed on April 5, 2006, by Aaron Finlay, Chief Financial Officer and Company Secretary. The registrant files annual reports under Form 20-F.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a corporate event rather than a financial statement.
Material Changes
The primary material event disclosed is the signing of a new evaluation agreement for a cardiovascular drug delivery system, as detailed in Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the context of the new agreement. No unusual items or contingencies are described in the provided text.
Investor Verification Checklist
- Verify the terms and scope of the new cardiovascular drug delivery evaluation agreement referenced in Exhibit 99.1.
- Confirm the commercial potential and timeline associated with the new agreement.
- Review subsequent filings for financial impact resulting from this agreement.